Monday 19 April: 08.00 - 09.00 am AEST
Preliminary analgesic evidence of cannabinoids delivered via NanoCelle® (submicron particle technology) and its further research addressing gaps in cannabis dosing efficacy
Results of a completed clinical study at RNSH investigating the pharmacokinetics (PK), safety, and tolerability of THC and CBD cannabinoids in a unique NanoCelle® formulation for the management of unrelieved pain in patients diagnosed with advanced cancers. Medlab’s water-soluble nanoparticle delivered cannabis-based medicine showed superior bioavailability and tolerability compared to ethanol-based delivery of cannabis-based medicines across the oro-buccal mucous membrane. The results of the study have demonstrated acceptable bioavailability, safety, tolerability, and evidence of analgesic efficacy in advanced cancers with bone metastasis.
Presenting an update on current research is important for those physicians who are currently prescribing medicinal cannabis for the patients where traditional therapies have failed. The level of current evidence on medicinal cannabis efficacy is low-moderated, and further research is needed for the safety of patients.
Dr Jeremy Henson is Medical Affairs Director at Medlab Clinical, Botany; Chief Career Medical Officer at Lakeview Private Hospital, Bella Vista; Senior Research Fellow at UNSW Sydney. Dr Henson has 18 years’ experience in cancer research, including the discovery of a novel type of cancer biomarker, development of a patented an assay to detect it and is exploiting these to create new precision cancer medicines. Dr Henson is a Clinical Tutor at the Faculty of Medicine, UNSW Sydney and is an active member of Cancer Australia Grant Review Committee and the Prince of Wales Clinical School PhD Student Review Committee.
Tuesday 20 April: 08.00 - 09.00 am AEST
Vagus Nerve Stimulation (nVNS) for the treatment of Cluster Headache and Migraine
Stimulating the vagus nerve affects many important autonomic functions in the brain and in the body, including neurotransmitter levels, inflammation levels and metabolism. nVNS therapy is now available in Australia.
In this session, Dr Peter Staats will introduce clinicians to non-invasive vagus nerve stimulation and its applications in the treatment of cluster headache and migraine including:
Dr Peter Staats (MD MBA) is the Chief Medical Officer and a co-founder of electroCore. He was the founder of the Division of Pain Medicine at Johns Hopkins University, where he was the director for 10 years. Dr Staats is internationally recognized for his work in developing neuromodulation strategies and for implementing minimally invasive procedures for chronic pain.
He has served as President of the Southern Pain Society , the American Society of interventional Pain Physicians ( ASIPP) the North American Neuromodulation Society (NANS) , New Jersey Society of Interventional Pain, chairman of the board of exam for the World Institute of Pain (WIP), and is currently the President of the WIP. He is also Chief Medical Officer for National Spine and Pain Centers, the largest pain practice in the United States.
Opioid stewardship in practice – discharging postoperative patients back to the community
Please join Professor Eric J. Visser (Churack Chair for Pain Education and Research at the University of Notre Dame Australia in Fremantle, and a specialist pain medicine physician and anesthesiologist at PainScience and St John of God Hospital Subiaco), and Jill Kelly (Nurse Practitioner Acute Pain Service St John of God Subiaco Hospital) as they give their perspective on the following:
The role of short term opioids following surgery for acute, severe pain is well recognised. Opioid stewardship principles when managing postoperative pain is imperative, as evidence suggests the pathway to a patient’s persistent opioid use can often start from the hospital environment post-surgery. The role of both the hospital and practitioners in the community in managing patients transitioning from hospital to community care are equally important. Principles such as avoiding the use of sustained release opioids for acute pain, prescribing individualised quantities of opioids reflective of the patient’s clinical need, as well as the importance of documented analgesic tapering plans will be discussed. The presentation will include the latest recommendations for tapering and stopping analgesics for acute pain from the new 2020 Therapeutic Guidelines: Pain and Analgesia.
Eric Visser (MBBS FANZCA FFPMANZCA) is the Churack Chair for Pain Education and Research at the University of Notre Dame Australia in Fremantle, and a specialist pain medicine physician and anesthesiologist at PainScience and St John of God Hospital Subiaco. He is also clinical senior lecturer in the School of Pharmacology and Anesthesiology at the University of Western Australia.
Eric has wide-ranging interests including pain education, acute pain service applications, spinal pain, headaches, CRPS and pharmacological pain management. He has a particular interest in peripheral neural blockade for chronic pain.
Jill Kelly is a Nurse Practitioner in the Acute Pain Service - St John of God Subiaco Hospital. Jill holds Master of Nursing (Pain Management) and Master of Nursing (Nurse Practitioner) qualifications. She was appointed as the first Acute Pain Service Nurse Practitioner in W.A and the first Nurse Practitioner to work in a private hospital in Australia in April 2012. Jill currently holds an Adjunct Senior Lecturer position within the University of Notre Dame, Fremantle teaching pain management to medical students and junior doctors both in the lecture room and at the patient bedside. In her Acute Pain Service Nurse Practitioner role, Jill provides pain management consultancy to inpatients as part of the multidisciplinary team. Jill also provides outpatient follow up and care to patients reviewed in the St John of God Acute Pain Service Transitional Clinic with the aim communication to general practitioners when opioid naïve post surgical patients are discharged from hospital prescribed opioids and or other analgesics previously prescribed by the Acute Pain Service at St John of God Subiaco Hospital.